About ArunA Bio
ArunA Bio is a company based in Athens (United States) founded in 2017. ArunA Bio has raised $38.51 million across 13 funding rounds from investors including HHS, NIH SBIR/STTR and Eshelman Ventures. ArunA Bio offers products and services including AB126 and Neural Exosome Platform. ArunA Bio operates in a competitive market with competitors including BioLife Solutions, Ribometrix, ReNAgade, RoosterBio and Creyon Bio, among others.
- Headquarter Athens, United States
- SectorsHealthcare
- Phone•••• ••••
- Website arunabio.com
- Social LinkedIn X
- Legal Name Aruna Bio, Inc
- Total Equity Funding$38.51M (USD)
in 13 rounds
- Latest Funding Round$679.41K (USD), Grant
Jun 2022
- InvestorsHHS
& 2 more
Products & Services of ArunA Bio
ArunA Bio offers a comprehensive portfolio of products and services, including AB126 and Neural Exosome Platform.
Exosome that reduces neuro-inflammation and promotes neuro-protection.
Platform enabling access across the blood-brain barrier for treatments.
Funding Insights of ArunA Bio
ArunA Bio has successfully raised a total of $38.51M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $679.41 thousand completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.51M
- Total Rounds 13
- Last Round Grant — $679,411
- First Round $189,593
(Jun 2008)
- Investors Count 3
Latest 10 of 13 funding rounds of ArunA Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $679,411 | Grant | – | – | |
| Apr 2021 | $10.8M | Series B | – | – | – |
| Sep 2019 | $4.5M | Grant | – | – | |
| Aug 2019 | $13.29M | Series B | – | Eshelman Ventures | – |
| Sep 2018 | $5.3M | Angel Round | – | – | – |
| Jul 2018 | $5.38M | Series A | – | – | – |
| Sep 2017 | $706,226 | Grant | – | – | |
| Sep 2017 | $5.03M | Grant | – | – | |
| Jul 2017 | $189,593 | Grant | – | – | |
| Jun 2017 | $225,000 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in ArunA Bio
ArunA Bio has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NIH SBIR/STTR and Eshelman Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | sbir.nih.gov | - | |
- | – | eshelmanventures.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for ArunA Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ArunA Bio
15 people are tracked at ArunA Bio (6 in leadership, 7 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Tyce Havens | Director Clinical Operations | Leadership |
Tracey Worthington-Stice | Chief Operating Officer | Leadership |
Steve Stice | Co-Founder, Chief Scientific Officer | Leadership |
Mark Sirgo | Chief Executive Officer | Leadership |
Raymond Swetenburg, PhD | Director, Discovery Research | Leadership |
Emily Baker | Director, Nonclinical Research | Leadership |
Tony Townley | Director | Board & advisors |
Russell C. Lindner | Director | Board & advisors |
Darren W. Devore | Director | Board & advisors |
John F. Mangan | Director | Board & advisors |
C. William Griffin | Chairman of the Board | Board & advisors |
Harold Ingalls | Director | Board & advisors |
Barry L. Storey | Director | Board & advisors |
Alinde Fojtik | Nonclinical Research Associate | Team |
Mac White | Research Scientist | Team |
Complete people profiles for ArunA Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ArunA Bio
3 dated milestones of ArunA Bio across 14 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $190K.
- Founded ArunA Bio is founded.
- Funding Latest funding round, Grant, of $679K.
Competitors of ArunA Bio
ArunA Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, Ribometrix, ReNAgade, RoosterBio and Creyon Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| ribometrix.com | 2016 | Raleigh, United States | $65.3M | 26 | RNA-targeted drug discovery platform using three-dimensional structural analysis is provided. | |
| renagadetx.com | 2021 | Cambridge, United States | $300M | 136 | RNA-based medicines are developed for treating multiple diseases. | |
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| creyonbio.com | 2019 | San Diego, United States | – | – | Oligonucleotide-based drug development platform is provided using AI models. | |
| duoningbio.com | 2005 | Shanghai, China | $14.88M | – | Serum-free cell culture media is supplied to biopharmaceutical industries. | |
| biotangents.co.uk | 2015 | Edinburgh, United Kingdom | $5.62M | 13 | Veterinary diagnostics products are developed for bovine viral diarrhea testing. | |
| fabricnano.com | 2018 | London, United Kingdom | $22.6M | 12 | DNA-based flow reactors are developed for biochemical production. |
Detailed competitors of ArunA Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ArunA Bio
The website of ArunA Bio (arunabio.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▼ 11.5% vs previous month
Latest news on Aruna Bio
Complete news archive for ArunA Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ArunA Bio
10 companies that operate in the same segment as ArunA Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ArunA Bio
ArunA Bio was founded in 2017.
ArunA Bio is headquartered in Athens, United States.
ArunA Bio is a funded company, having raised a total of $38.51M across 13 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Jun 2008.
Founded in 2017 and based in Athens, United States, ArunA Bio operates in the biotechnology sector. A neural exosome platform is utilized to create therapeutics that cross the blood-brain barrier. Anti-inflammatory, self-repair, and protective mechanisms in the body are enhanced to address neurodegenerative disorders. The lead candidate, AB126, targets stroke, Parkinsons disease, and multiple sclerosis.
ArunA Bio's top competitors include FabricNano, RoosterBio and BioLife Solutions.
ArunA Bio offers AB126 and Neural Exosome Platform.
ArunA Bio has 3 investors. Key investors include HHS, NIH SBIR/STTR, and Eshelman Ventures.
ArunA Bio operates through Aruna Bio, Inc.